BioCentury | Feb 27, 2021
Deals

Feb. 26 Quick Takes: Venrock leads Artiva’s crossover-laden $120M series B; plus Roivant-Silicon, Origin, Sino-Akeso, Tricida, LISCure

...NSCLC endpointAn interim Phase III analysis showed anti-PD-1 mAb penpulimab (AK105) from Sino Biopharmaceutical Ltd. (HKEX:1177) and Akeso Inc....
BioCentury | Jan 16, 2021
Product Development

Arcus’ CD73 inhibitor challenges AZ’s oleclumab, at least six others follow in oncology: Data Byte

...Koch [MERGED] AstraZeneca plc I-Mab Biopharma Surface Oncology Inc. Novartis AG Corvus Pharmaceuticals Inc. Tracon Pharmaceuticals Inc. Eli Lilly and Co. Arcus Biosciences Inc. Akeso Inc. AstraZeneca...
BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

...and PK data for its anti-CD47 mAb IBI188, and Akeso...
BioCentury | Nov 11, 2020
Deals

Previewing CD47 efficacy data at SITC & ASH: Data Byte

...and PK data for its anti-CD47 mAb IBI188, and Akeso...
BioCentury | Oct 9, 2020
Finance

Everest balances local, international offerings in IPO that could be biggest yet on Hong Kong biotech chapter

...the international offering.Other biotechs that have gone public in Hong Kong this year, such as Akeso Inc....
BioCentury | Jun 4, 2020
Finance

Everest to fund late-stage trials with $310M mountain of fresh cash

...in December 2019, which valued the company at HK$9.1 billion. And in April, Zhongshan, China-based Akeso Inc....
BioCentury | May 22, 2020
Finance

Kintor IPO latest sign of Hong Kong’s maturing biotech chapter

...for lead androgen receptor antagonist proxalutamide (GT0918) to treat metastatic castration-resistant prostate cancer Paul Bonanos, Associate Editor Akeso Inc. IPO...
BioCentury | May 16, 2020
Finance

HKEX’s biotech chapter shows all the signs of a sustainable market

...valuation process. Deals for Alphamab Oncology Ltd. (HKEX:9966), InnoCare Pharma Ltd. (HKEX:9969) and most recently Akeso Inc....
...last 18 months, with the last three IPOs seeing retail demand of 200x or more; Akeso...
...Akeso’s CEO Michelle Xia, who said that because of the company’s large cornerstone investor allocation, Akeso...
BioCentury | May 14, 2020
Finance

May 13 Quick Takes: MyoKardia raises $551M; plus Legend looks to NASDAQ for IPO and ADC, Travecta, QureBio, Kintor, Lantern, Kiromic

...T cell or vaccine based therapies. Elizabeth S. Eaton and Hongjiang Li, Staff Writers JNJ-68284528, JNJ-4528 (LCAR-B38M) Proxalutamide (GT0918) Akeso Inc. MyoKardia...
BioCentury | Apr 29, 2020
Product Development

Highlights from AACR’s first annual virtual meeting show mixed results for I/O combos, promise for new targets, modalities

...BCIQ database, COM701 is the only molecule in development that targets the checkpoint pathway PVRIG. Akeso Inc....
...largest IPO of the year on the Hong Kong exchange’s biotech chapter (see “Antibody Company Akeso...
Items per page:
1 - 10 of 28
BioCentury | Feb 27, 2021
Deals

Feb. 26 Quick Takes: Venrock leads Artiva’s crossover-laden $120M series B; plus Roivant-Silicon, Origin, Sino-Akeso, Tricida, LISCure

...NSCLC endpointAn interim Phase III analysis showed anti-PD-1 mAb penpulimab (AK105) from Sino Biopharmaceutical Ltd. (HKEX:1177) and Akeso Inc....
BioCentury | Jan 16, 2021
Product Development

Arcus’ CD73 inhibitor challenges AZ’s oleclumab, at least six others follow in oncology: Data Byte

...Koch [MERGED] AstraZeneca plc I-Mab Biopharma Surface Oncology Inc. Novartis AG Corvus Pharmaceuticals Inc. Tracon Pharmaceuticals Inc. Eli Lilly and Co. Arcus Biosciences Inc. Akeso Inc. AstraZeneca...
BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

...and PK data for its anti-CD47 mAb IBI188, and Akeso...
BioCentury | Nov 11, 2020
Deals

Previewing CD47 efficacy data at SITC & ASH: Data Byte

...and PK data for its anti-CD47 mAb IBI188, and Akeso...
BioCentury | Oct 9, 2020
Finance

Everest balances local, international offerings in IPO that could be biggest yet on Hong Kong biotech chapter

...the international offering.Other biotechs that have gone public in Hong Kong this year, such as Akeso Inc....
BioCentury | Jun 4, 2020
Finance

Everest to fund late-stage trials with $310M mountain of fresh cash

...in December 2019, which valued the company at HK$9.1 billion. And in April, Zhongshan, China-based Akeso Inc....
BioCentury | May 22, 2020
Finance

Kintor IPO latest sign of Hong Kong’s maturing biotech chapter

...for lead androgen receptor antagonist proxalutamide (GT0918) to treat metastatic castration-resistant prostate cancer Paul Bonanos, Associate Editor Akeso Inc. IPO...
BioCentury | May 16, 2020
Finance

HKEX’s biotech chapter shows all the signs of a sustainable market

...valuation process. Deals for Alphamab Oncology Ltd. (HKEX:9966), InnoCare Pharma Ltd. (HKEX:9969) and most recently Akeso Inc....
...last 18 months, with the last three IPOs seeing retail demand of 200x or more; Akeso...
...Akeso’s CEO Michelle Xia, who said that because of the company’s large cornerstone investor allocation, Akeso...
BioCentury | May 14, 2020
Finance

May 13 Quick Takes: MyoKardia raises $551M; plus Legend looks to NASDAQ for IPO and ADC, Travecta, QureBio, Kintor, Lantern, Kiromic

...T cell or vaccine based therapies. Elizabeth S. Eaton and Hongjiang Li, Staff Writers JNJ-68284528, JNJ-4528 (LCAR-B38M) Proxalutamide (GT0918) Akeso Inc. MyoKardia...
BioCentury | Apr 29, 2020
Product Development

Highlights from AACR’s first annual virtual meeting show mixed results for I/O combos, promise for new targets, modalities

...BCIQ database, COM701 is the only molecule in development that targets the checkpoint pathway PVRIG. Akeso Inc....
...largest IPO of the year on the Hong Kong exchange’s biotech chapter (see “Antibody Company Akeso...
Items per page:
1 - 10 of 28